Transcription Activator-Like Effector Nucleases
"Transcription Activator-Like Effector Nucleases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Artificial nucleases that cleave DNA at a defined distance from specific DNA sequences recognized by TRANSCRIPTION ACTIVATOR-LIKE EFFECTORS. They are composed of an endodeoxyribonuclease fused to DNA-binding domains of the transcription activator-like effectors.
| Descriptor ID |
D000069896
|
| MeSH Number(s) |
D08.811.277.352.335.350.850 D12.776.828.300.850
|
| Concept/Terms |
Transcription Activator-Like Effector Nucleases- Transcription Activator-Like Effector Nucleases
- Transcription Activator Like Effector Nucleases
- Nucleases, Transcription Activator-Like Effector
- Nucleases, Transcription Activator Like Effector
- TALENs
|
Below are MeSH descriptors whose meaning is more general than "Transcription Activator-Like Effector Nucleases".
Below are MeSH descriptors whose meaning is more specific than "Transcription Activator-Like Effector Nucleases".
This graph shows the total number of publications written about "Transcription Activator-Like Effector Nucleases" by people in this website by year, and whether "Transcription Activator-Like Effector Nucleases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Transcription Activator-Like Effector Nucleases" by people in Profiles.
-
Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing. Stem Cell Res. 2018 05; 29:215-219.
-
A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing. Stem Cell Res. 2018 03; 27:131-135.
-
Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy. Mol Ther. 2016 08; 24(8):1378-87.